Medical device company Zimmer Biomet (NYSE: ZBH) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $2.09 billion. Its non-GAAP profit of $2.09 per share was 12.2% above analysts’ consensus estimates.

Is now the time to buy ZBH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Zimmer Biomet’s first quarter of 2026 results exceeded Wall Street’s expectations for both revenue and non-GAAP earnings, but the market responded negatively. Management pointed to ongoing changes in its U.S. sales force, robust technology sales, and new product launches as key factors in the quarter. CEO Ivan Tornos cited a “greater than 20% increase in partial knee sales” driven by the Oxford Partial Cementless Knee, while highlighting sales disruptions from brand rationalization and account losses. The company acknowledged some cautiousness around continued transformation and recent account transitions, which contributed to operational disruptions and tempered the positive momentum.

Looking ahead, Zimmer Biomet’s updated guidance is founded on expected margin improvement, continued investments in technology and commercial infrastructure, and cautious optimism regarding its ongoing sales force transition. Management emphasized that the company is “making fairly substantial changes in a variety of fronts, go-to-market models here in the U.S. [and] some changes in emerging markets.” CEO Ivan Tornos expressed confidence in the current trajectory, citing the ramp-up of new products and strong technology pipeline as reasons for optimism, but underscored the need for prudence given the early stage of these initiatives.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to the successful ramp of new technology products, progress in transitioning to a dedicated sales force, and operational improvements, while noting some short-term disruptions from these strategic shifts.

• Sales force transformation progress: Zimmer Biomet continued its transition to a more dedicated and specialized U.S. sales force, reducing non-dedicated representatives from 66% to just under 60%. This shift led to higher productivity and improved sales in territories where changes were implemented, although it also caused temporary disruption and the loss of two large accounts during the quarter.
• Technology and robotics momentum: Technology and data, bone cement, and surgical businesses grew nearly 12%, driven by double-digit growth in ROSA and TMINI robotic platforms. The company completed enrollment for its Monogram AI-driven robotic system clinical study and anticipates U.S. approval for the semiautonomous version in early 2027.
• Product portfolio rationalization: The company continued to phase out legacy knee implants, such as NextGen, in favor of newer products, which contributed to some short-term pressure in U.S. knee sales but is expected to strengthen the brand portfolio over time.
• International business and distributor changes: International growth trailed the U.S. this quarter, primarily due to tougher comparisons, ongoing distributor consolidation, and one-time order delays in emerging markets, the Middle East, and China. Management expects mid-single-digit growth outside the U.S. in the second half of the year as these changes stabilize.
• Leadership transition: CFO Suky Upadhyay announced his departure, with Paul Stellato named interim CFO. Management emphasized continuity in capital allocation and strategy execution during this transition, citing Stellato’s experience and involvement in recent acquisitions and financial planning.

Drivers of Future Performance

Zimmer Biomet’s outlook for 2026 hinges on continued execution of its sales force transformation, accelerated technology adoption, and the integration of new product launches, balanced by ongoing market and operational risks.

• Sales force transformation impact: Management expects that the transition to a more dedicated U.S. sales force will drive productivity and sales improvements across key product lines. However, the company flagged the risk of ongoing disruption as the transformation continues through 2027, with potential impacts on account retention and near-term sales growth.
• Technology-driven growth: The ramp-up of robotics and smart implant platforms, such as Monogram and Persona IQ, is expected to contribute meaningfully to future revenue. Management highlighted heavy investments in hiring clinical sales representatives and in clinical evidence generation to support these launches, but acknowledged the need for widespread adoption and payer acceptance to realize the full benefit.
• Pricing and macroeconomic headwinds: The company maintained guidance for up to 100 basis points of price erosion and cited ongoing competitive and macroeconomic pressures—such as potential impacts from tariffs, Middle East supply disruptions, and changes in international distributor networks—as risks to maintaining current margin levels.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will closely watch (1) the pace and impact of the U.S. sales force transformation on productivity and account retention, (2) adoption and clinical rollout of the Monogram robotic system and other new technology platforms, and (3) stabilization of international operations as distributor changes and product rationalization play out. Progress in these areas will be critical for assessing Zimmer Biomet’s ability to meet its long-term growth and margin goals.

Zimmer Biomet currently trades at $83.31, down from $92.59 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.